Dose-Limiting Toxicities of Paclitaxel in Breast Cancer Patients: Studying Interactions Between Pharmacokinetics, Physical Activity, and Body Composition—A Protocol for an Observational Cohort Study
Authors:
- Len De NysLNLen De Nys
- Anita Barzegar-FallahABAnita Barzegar-Fallah
- Katrien LanckmansKLKatrien Lanckmans
- Stephane SteurbautSSStephane Steurbaut
- David BeckwéeDBDavid Beckwée
- Amy de Haar-HollemanAHAmy de Haar-Holleman
- Steven ProvynSPSteven Provyn
- Elke GasthuysEGElke Gasthuys
- Sofie Vande CasteeleSCSofie Vande Casteele
- Pieter-Jan De SutterPSPieter-Jan De Sutter
- An VermeulenAVAn Vermeulen
- Jan Van BocxlaerJBJan Van Bocxlaer
Open Access
Abstract
Background/Objectives: Paclitaxel (PTX), a commonly used chemotherapy for breast cancer (BC), is associated with dose-limiting toxicities (DLTs) such as peripheral neuropathy and neutropenia. These toxicities frequently lead to dose reductions, treatment delays, or therapy discontinuation, negatively affecting patients’ quality of life and clinical outcomes. Current dosing strategies based on body surface area (BSA) fail to account for individual variations in body composition (skeletal muscle mass (SMM) and adipose tissue (AT) mass) and physical activity (PA), which can influence drug metabolism and toxicity. This study aims to explore the relationships between PTX pharmacokinetics, body composition, and PA to predict DLTs. Methods: This single-group observational cohort study will recruit 40 female BC patients undergoing PTX treatment. Data collection will include plasma PTX concentrations, body composition assessments (using dual X-ray absorptiometry and bioelectrical impedance analysis), PA measurements (via accelerometers), and questionnaires to assess BC-related health-related quality of life, chemotherapy-induced peripheral neuropathy, and neutropenia during the PTX schedule using validated questionnaires. Dose-limiting toxicities will be graded according to the Common Terminology Criteria for Adverse Events v5.0 (grade 3 or higher). This protocol is designed to develop a population-based PK-PD model that predicts the occurrence of chemotherapy-induced peripheral neuropathy and neutropenia in women with stage II or III BC undergoing PTX therapy, focusing on explanatory outcomes related to SMM, AT mass, and PA.Keywords
Funding Information
- Kom op tegen Kanker (KotK_VUB/2022/13163/1)
This publication has 54 references indexed in Scilit:
- Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-AnalysisThe Oncologist, 2021
- An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45Annals of Oncology, 2020
- Sarcopenia: A Time for Action. An SCWD Position PaperJournal of Cachexia, Sarcopenia and Muscle, 2019
- Breast Cancer TreatmentJAMA, 2019
- Habitual recreational physical activity is associated with significantly improved survival in cancer patients: evidence from the Roswell Park Data Bank and BioRepositoryCancer Causes & Control, 2018
- Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapyBreast Cancer Research and Treatment, 2018
- The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I–III colorectal cancer: a population‐based cohort study (C‐SCANS)Journal of Cachexia, Sarcopenia and Muscle, 2018
- Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practiceBreast Cancer Research and Treatment, 2012
- Effects of physical activity on common side effects of breast cancer treatmentBreast Cancer, 2011
- An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicityCancer Chemotherapy and Pharmacology, 2010